“By the year 2015, half of all medical images will be in the cloud”

Dell to Host Agfa Medical Imaging Database in the Cloud

Dell's cloud infrastructure will host Agfa's imaging archive to allow doctors to incorporate images into electronic health records.

Dell has announced it will host Agfa Healthcare's medical imaging archive in the cloud.

The cloud will provide the storage capacity and processing power as doctors look for ways to make medical images compatible with electronic health records (EHRs).

Cloud computing will be an essential factor in this effort, especially when IT budgets are tight, according to Dr. Jamie Coffin, vice president and general manager of Dell Healthcare and Life Sciences.

"The world is moving to a patient-centric view of the [EHR]," Coffin told eWEEK. "You have to start to think about digital radiology, pathology, genomics and figure out how to store this in a format where you take and use it wherever your clinician is."

Agfa's medical imaging archive, called Imaging Clinical Information System (ICIS), is a central repository that allows doctors to capture, store and exchange medical images.

Using ICIS in Dell's cloud, clinicians can capture a medical image and related metadata and "marry" it with the patient demographics in an EHR, Lenny Reznik, director of enterprise imaging and information solutions for Agfa HealthCare, told eWEEK. "Their clinical information system allows you to image-enable all of the data that they have in their [picture archiving and communications systems, or PACS] into the [EHR]," said Coffin. "The idea is that they store it in the cloud, and customers can access it from wherever they are and whatever platform they're on."

Dell and Agfa announced their partnership on June 7.

ICIS incorporates the Impax Data Center, which unifies patient records across regions, hospital facilities and departments. As a vendor-neutral system, ICIS can store images from various PACS.

The Agfa platform also includes the Xero Technology Viewer, a tool that allows doctors to stream the images from any Web-enabled device. The image viewer lets doctors embed images directly into an EHR.

Agfa customers will be able to access images either in Agfa's ICIS or Dell's Cloud Clinical Archive, said Coffin.

Dell announced a similar agreement with Siemens in February in which the two companies would collaborate on a vendor-neutral image archive in the cloud.

In addition, Dell will offer its Cloud Clinical Recovery platform to Agfa customers to provide disaster protection. Medical facilities using Agfa's imaging archive will be able to access additional analytics and data services in the future, said Coffin.

Hospitals with 300 to 400 beds that can't afford a data center infrastructure or the personnel to operate it will be able to manage their images and data in the cloud, said Coffin.

"By the year 2015, half of all medical images will be in the cloud," Reznik predicted.

By allowing ICIS to manage the archiving of radiology images, doctors are free to concentrate on treating patients, according to Agfa. Storing images in the cloud allows providers to track patients over time and maintain longitudinal medical imaging record access, Michael Green, Agfa HealthCare's president and CEO of Americas region, said in a statement.

Storing the medical images in the cloud will allow doctors' offices or medical centers to manage data-intensive images when they lack physical space to store their own servers.

"A single pathology slide can be like 6GB of data because it's a high-resolution image," Coffin noted. "It really brings an ROI to the customers they've never been able to get before [from] on-site image management."

In addition, archiving medical images in the cloud allows health care providers to meet the Stage 2 requirements on meaningful use of EHRs, according to Dell. Medical image viewing is an optional menu measure for achieving Stage 2 compliance.

As health information exchanges (HIEs) continue to connect data from diverse EHR platforms, the cloud will be an important foundation as data elements such as imaging, pathology and genomics are incorporated into the exchanges, Coffin suggested.

 

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Should Physicians Invest in Facebook?

via Medscape

Physicians and other investors often kick themselves for not having grabbed the opportunity to invest early in Microsoft, Google, or other companies whose stock price skyrocketed. Many doctors think that Facebook shares present the same type of once-in-a-lifetime opportunity. Are they right?

The debacle of Facebook's initial public offering should make anyone leery of jumping into an IPO, if they weren't already skeptical about them.

But it begs the question of whether one should invest in the social networking site that has revolutionized how people communicate with each other.

The much-anticipated IPO, which offered 421 million shares at $38 and valued Facebook at more than $100 billion, was the subject of incredible hype beforehand and an emotional backlash afterwards as the price plummeted nearly 20% in the first few days of trading.

Analysts branded it a "broken IPO" and one compared the stock to a "falling knife" that no one wanted to grab.

MarketWatch commentator Chuck Jaffe scolded anyone who believed the hype by labeling the IPO "the stupid investment of the week," and said that the experience should teach investors once and for all that the letters IPO really stand for "it's probably overpriced."

Subsequent trading seemed to drive that point home as Facebook shares continued to dive, declining more than 30% from the IPO price of $38. The head of Morgan Stanley, which was the lead manager on the share sale, said investors were "naive" if they thought they would profit on the first day of trading.

Inspired by Other Tech Stock Winners

But optimists had visions of another Google dancing in their heads, which saw its share price double in the first few months of trading and quintuple within 2 years (though it has oscillated around $600 since then, with occasional bigger dips).

Apple, whose share price has risen steadily over the past 5 years, quintupling in value, probably ranks as the most successful big tech share. Apple, however, makes things that people buy -- iPhones, iPads, laptops, PCs -- and also makes a ton of money raking off part of the proceeds from content that gets sold to people using these devices.

Facebook, and Google for that matter, have more intangible assets -- hundreds of millions of Internet users who leave behind useful traces about what they're interested in buying.

Google, though, has proven that it knows how to deliver advertising messages to people who are interested in them, while Facebook has yet to figure out just how to insert commercials into the social networking experience.

General Motors drove home that point with the announcement just before Facebook's IPO that it was pulling its advertising from the site because it had seen no measurable return on that investment.

Facebook is nonetheless the 800-pound gorilla in a social networking phenomenon that has swept the globe. And while many still think it is just a passing fad, you'd have a hard time convincing anyone under 30 that such networking is not a permanent fixture in their lives.

Why You Should or Shouldn't Snap Up the Stock

For now, it seems likely that Facebook stock will be buffeted by high-frequency traders looking for quick profits in a volatile issue. More shares will be hitting the market in coming months as IPO lockups expire, so that it will be some time before a reliable price picture emerges. Some analysts see a chance of the stock going as low as $10, while others are tipping $44 in the short term.

Obviously nobody knows. Every investor has to make his or her own decision, and you will probably want to consult with your financial advisor in figuring it out for yourself. But answering the question of whether you should invest in Facebook makes for an interesting case study in which to review some tried-and-true rules on investing.

1. Don't invest in IPOs

Jaffe is right. Pricing IPOs has always involved balancing the desire of the sellers (the founders and investors who got the new company off the ground) for the highest possible price and the preference of the buyers (institutions and individuals) for the price that will allow the greatest chance for future gains. That balance has tilted decidedly in favor of the sellers in recent years, and many analysts are saying that Facebook's $38 IPO price was too high and will make it difficult for other tech companies to go public.

Although some institutional investors may feel it is necessary to get in on the ground floor with a stock that could become a must-own issue, there's very little reason for retail investors to feel that way.

There was a time when a stock that sold for $38 might never look back and you wouldn't have a chance to get it below $50 or $75. But that hasn't happened in a while, and your chances of getting lucky on one of those issues are not great.

In this case, you would have been better off waiting a day or two and picking up the stock for $31 -- if you think it's a good investment.

2. Invest in what you know

It would almost certainly be foolish to invest in Facebook unless you were an active user on the network or could talk to friends, children, or grandchildren who are. Facebook's main asset is its 900 million active users, so it's very important to have a feel for what they're thinking to understand the future of the company.

Rupert Murdoch's News Corp. missed the boat when it acquired MySpace, an early Facebook rival and the market leader at the time, for $580 million in 2005 only to sell it just 6 years later for $35 million after MySpace lost out to Facebook.

Analysts say that Facebook users -- the college generation that first embraced it a decade ago -- are already "aging" and that younger people today have numerous alternatives, such as Twitter, Pinterest, and Flickr, among others. Will members continue to use Facebook as faithfully as they have done, or will the switch from PCs to mobile phones as the main communication device favor some of these other formats?

Facebook has had some difficulty making the transition to smart phones, and the company's purchase of the photo-sharing service Instagram for $1 billion this spring was designed to help close that gap.

In a case like Facebook, your view of the company's future will depend a lot on what you think of Mark Zuckerberg, the young man who founded it and masterminded its rise as the premier social networking site. Can Zuckerberg continue to reinvent Facebook in a fast-moving tech environment in the way that Steve Jobs kept reinventing Apple? Reports out just this week say that Facebook is getting serious about developing its own smart phone and may spend another $1 billion buying the Norwegian developer of a versatile browser.

Other Important Considerations

3. Limit your exposure

Where does an investment in Facebook fit into your portfolio? Is it a purely speculative stock or do you see it as a key component of a 21st century portfolio? What is your timeframe? Do you want to see a strong gain and early exit or is this a buy-and-hold stock?

Because Facebook is not only a new company but basically a whole new industry -- social networking -- it is difficult to evaluate its performance so far or to make any forecasts. There is no track record or benchmark for this industry.

The phenomenon of social networking could vanish as quickly as it appeared, or Facebook could begin to look like a dinosaur as newer, nimbler rivals appear on the scene. For that reason, you have to be ready to lose your entire stake in Facebook or set a strict limit for selling if it reaches the price marking how much you're willing to lose. "Strict" means that you really sell at that price and don't fall into the retail investor's trap of holding out for the stock to come back.

If you go into the stock for a relatively quick gain, set a deadline depending on the timeframe for this investment. Is "quick" 1 year or 5 years? You could have sold Google after 2 years, for instance, and booked the same gains as if you had held it and sold now.

4. What is your opportunity cost?

If you invest in Facebook now, will it make more money for you than other investments would? Value investors look for stocks that are undervalued. A lot of people concluded that Facebook was overvalued when it plummeted in the first few days of trading, but some analysts felt that it was undervalued at the IPO price of $38 and really undervalued at $31.

Facebook has no track record, so it might be easier to identify other stocks as undervalued based on their performance. David Rolfe of the RiverPark/Wedgewood Fund suggested at the time of the Facebook IPO that investors would be better off putting their money into proven stocks such as Warren Buffett's Berkshire Hathaway and Apple, which seem to be undervalued now based on their past performance.

5. Know what you're looking for in an investment

Some retail investors are abandoning the stock market, which they see as a casino rigged in favor of the house. The Facebook IPO seems to be a poster child for everything that's wrong with Wall Street now -- institutional investors getting better information, technology favoring the big investors over small investors, greed overcoming fairness.

But the very size of the company and of the initial float of more than 400 million shares should make Facebook less volatile once the waves from the IPO finally subside. In other words, if Facebook has a future, buying shares is probably a good way to benefit from it, regardless of the IPO glitches.

Many investors would prefer to hit a home run with a great stock pick than play the small ball of eking out gains through a well-balanced mutual fund. But that can lead to a lot of attempts and failures. Are you in a position now in your career or your retirement planning that you can afford to take a big loss if it means you could potentially have a huge win? If so, maybe you will want to step up to the plate and take a swing.

via Medscape - Medscape Business of Medicine © 2012 WebMD, LLC

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Eastman Kodak files for auction of Digital Imaging patents

 

Kodak(Reuters) - Eastman Kodak Co filed a motion on Monday seeking approval of bidding procedures for bankruptcy auction of its Digital Capture and Kodak imaging Systems and Services patent portfolios, which together comprise more than 1,100 patents.

Kodak's motion outlines a sale process such that only the winning bidder and the successful bid amount will be publicly announced at the end of the auction, it said in a statement.

Kodak, now in bankruptcy, expects the motion to be heard by the Court on July 2, with the auction being held in early August and the winning bidder being announced by August 13.

"In filing these proposed procedures in advance of the June 30 deadline in our lending agreement, we are moving ahead as quickly as possible with the process of monetizing our digital imaging patent portfolio," Timothy Lynch, Kodak's Chief Intellectual Property Officer said.

The company's financial adviser, Lazard, has marketed these assets over the past 12 months, and 20 parties have signed confidentiality agreements to date, the company revealed in a statement.

Kodak, which invented the handheld camera and the digital camera, filed for bankruptcy protection on January 19.

via Yahoo! Finance

Also see: Kodak Posts $114 Million Loss (May 2008) 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Mainland Medical lab named for longtime doctor

Special to The Daily News

TEXAS CITY Mainland Medical Center dedicated the hospitals lab in honor of Dr. Herman Koester. Koester was the chief of pathology for Galveston County Hospital, now Mainland Medical Center, for 30 years.

Herman founded Mainland Pathology Associates and Physicians Laboratory in 1975, and he and his partners also managed the pathology departments at St. Johns Hospital and the former Danforth Hospital in Texas City.

Dr. Herman Koester was a devoted husband, father, grandfather and great-grandfather who passed away on Monday, Dec. 19, 2011, hospital officials said. It is with great honor that he is remembered through his dedication to the community and that the laboratory at Mainland Medical Center in Texas City be forevermore known as the Herman Lott Koester Laboratory.

In addition, Koester was chief of staff at Mainland Medical Center and a member of the hospitals board of directors until his retirement. Koester was a member of the Galveston County Medical Society, the Texas Medical Association, the College of American Pathologists, the American Society of Clinical Pathologists, the American Society of Cytologists and the American Medical Association.

He served as a member of the board of the Blood Bank, College of the Mainland board of trustees and the University of Texas Medical Branch Development Board.

Paula Cashion is the Marketing Coordinator for Mainland Medical Center.

Read this article:
Mainland Medical lab named for longtime doctor

AccelPath, Inc. Announces Dr. Keith J. Kaplan, M.D. Continues Role as Chairman on Company’s Medical Advisory Board

GAITHERSBURG, Md.--(BUSINESS WIRE)--

AccelPath, Inc. (ACLP) (AccelPath or the Company) announced today that Dr. Keith J. Kaplan, M.D. continues his role as Chairman and active member of the Companys Medical Advisory Board.

Keith J. Kaplan, MD is a pathologist and Chief Information Officer (CIO) of Carolinas Pathology Group (CPG), Celligent Diagnostics and Diligent Billing and Management. As CIO, Dr. Kaplan is responsible for all aspects of informatics strategies, operations, and projects and processes that encompass laboratory, healthcare and research information systems for Carolinas Pathology Group. Prior to joining CPG, Dr. Kaplan was a surgical pathologist at Mayo Clinic, Rochester, Minnesota and also held the academic post of associate professor of pathology of Mayo Medical School.

Dr. Kaplan is a graduate of Michigan State University, a graduate of Northwestern University Feinberg School of Medicine and completed residency training in anatomic and clinical pathology at Walter Reed Army Medical Center, Washington, DC. While at Walter Reed, Dr. Kaplan was named Resident of the Year and, in conjunction with the Armed Forces Institute of Pathology, Dr. Kaplan founded and directed the Army Telepathology Program. This Program connected 25 hospitals internationally for consultation via telepathology. Dr. Kaplan also served as the Medical Director and Consulting Pathologist of Laboratory Services at Keller Army Hospital in West Point, New York.

Dr. Kaplan is board certified in anatomic and clinical pathology. His subspecialty interests include gastrointestinal and hepatic pathology, cytopathology and pathology informatics as well as research interests in gastrointestinal and hepatobiliary pathology, hyperspectral imaging, image analysis and the use of Web 2.0 tools in pathology. He has authored over 60 peer-reviewed scientific articles, book chapters, editorials and scientific abstracts and frequently lectures at both national and international meetings on topics related to pathology informatics.

Dr. Kaplan currently serves as a member of the College of American Pathologists, American Society of Clinical Pathology and the American Society of Cytopathology as well as the American Pathology Foundation. He is also an executive board member of the Digital Pathology Association. Dr. Kaplan has previously served as a member of the College of American Pathologists Informatics Committee, Standards Committee, and Instrumentation Resource Committee and as co-chair of the American Telemedicine Association Telepathology Special Interest Group.

We are very pleased with our collaborative relationship with Dr. Kaplan, stated Shekhar Wadekar, AccelPaths Chairman and Chief Executive Officer. Dr. Kaplans expertise in the technical and medical components of digital telepathology (through his experiences at Walter Reed Army Medical Center / the Armed Forces Institute of Pathology, founding and directing the Army Telepathology Program, and industry experience as a practicing pathologist) provides us significant insights while we enhance our proprietary digital telepathology solutions. He will also be invaluable as we further apply those to existing pathology laboratories and related service providers.

About AccelPath

AccelPath provides technology solutions that play a key role in delivering information required for diagnosis of diseases and other pathologic conditions with and through its associated institutional pathologists. The medical institutions, with whom the Company partners, prepare comprehensive diagnostic reports of a patients condition and consult with referring physicians to help determine the most appropriate treatment. Such diagnostic reports enable the early detection of disease, allowing referring physicians to make informed and timely treatment decisions that improve their patients health in a cost-effective manner. The Company seeks out referring physicians and histology laboratories in need of high-quality pathology interpretations and manages HIPAA-compliant digital case delivery and reporting while developing comprehensive solutions for managing medical information.

AccelPath is currently focused on the $14 billion anatomic pathology market in the US. The Companys business model builds upon the expertise of experienced pathologists to provide seamless, reliable and comprehensive pathology and special test offerings to referring physicians using conventional and digital technologies.The Company establishes longstanding relationships with the referring physicians as a result of focused delivery of its partners diagnostic services, personalized responses and frequent consultations, and its proprietary flexible information technology, or IT, solutions that are customizable to the referring physicians or laboratories as well as the pathologists needs. Such diagnostic reports often enable the early detection of disease, allowing referring physicians to make informed and timely treatment decisions that improve their patients health in a cost-effective manner. AccelPaths IT and communications platform enables it to efficiently and securely deliver diagnostic reports to referring physicians. In addition, AccelPaths IT platform enables close tracking and monitoring of medical statistics.

More here:
AccelPath, Inc. Announces Dr. Keith J. Kaplan, M.D. Continues Role as Chairman on Company’s Medical Advisory Board

PathXL and Olympus Soft Imaging Solutions Announce Digital Pathology Education Partnership

Olympus Soft Imaging Solutions GmbH (OSIS), a leading system solution provider in microscopy and PathXL Ltd., a company that specialises in developing web-based software for digital pathology, announced today a non-exclusive worldwide original equipment manufacturer (OEM) software distribution agreement for PathXL’s Digital Pathology Education Solutions.  Under the partnership, OSIS will market and sell PathXL’s solutions for training, development, education, testing and quality assessment purposes to the Digital Scientific Education market. 

OSIS, well-known in the scientific micro imaging field, will expand their offering to include digital pathology education applications; Olympus E-Learning Solution powered by PathXL will be showcased at the 11th European Congress of Telepathology and 5th International Congress on Virtual Microscopy in Venice, 6 - 9 June.

News-olympus

Olympus E-Learning Solution will enable users to effectively create and manage digital slides and other content, publish online, share and view from anywhere in the world. The solution provides on-line virtual microscopy teaching, educational, CPD and competency exam resources in minutes, significantly enhancing student, trainee and the professional experience.  The solution also incorporates a platform which supports early stage training for residents in pathology.  Trainees can work through real cases and assess how well they have performed.  The software will be available directly from OSIS worldwide.

Commenting on the agreement, Dr. Tobias Schilling, Section Manager of Olympus Soft Imaging Solutions, stated

“The OLYMPUS VS120 is an advanced digital slide scanning system for brightfield and fluorescence applications.  It offers a complete spectrum of functionality for Research, Training including Remote Conferencing and Consultations tools. With the integration of PathXL’s Digital Pathology Education Solutions we enlarge our solutions by a complete Digital Learning Environment.  Our customers will benefit from PathXL’s long-term experience in the field of digital pathology and a fully integrated solution offered by Olympus.”

Philip Murray, Executive Vice President of PathXL, stated

“We are delighted to enter this strategic partnership with Olympus Soft Imaging Solutions.  PathXL are specialists in delivering digital pathology education software applications.  The partnership enables the company to continue its rapid expansion throughout Europe, UK and beyond.  Olympus Soft Imaging Solutions and PathXL are well positioned to be the market leader within digital pathology medical education.”

About PathXL

PathXL specialises in web-based software and workflows for Digital Pathology.  Its PathXL™ Manager product provides a robust, secure and open web-based platform to enable digital pathology users across all fields to manage, view and collaborate around virtual slides easily and efficiently.  In addition, PathXL provides a range of applications and workflows on top of PathXL™ Manager to deliver specific solutions to pathologists, scientists and students in Education, Research, Clinical and Biobanking settings.  PathXL also provides a full range of supporting services, including scanning, hosting, image analysis and consultancy.  PathXL operates in the UK, Europe and North America.

PathXL is a privately owned company, headquartered in Belfast, Northern Ireland.  For more information please visit: http://www.pathxl.com

About Olympus Soft Imaging Solutions GmbH

Olympus Soft Imaging Solutions strives to develop and build effective hardware and software solutions for microscopic image processing and analysis.  Their team of engineers, scientists, and service specialists provide complete training and service to satisfied customers in sciences and industries.  Olympus Soft Imaging Solutions generates synergies, offering a unique opportunity for establishing a “Center of Competence and Excellence” for Olympus operations in the scientific micro imaging field.

For more information visit: http://www.olympus-sis.com/

 

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Travel Award Announcement for Pathology Visions 2012

 

Travel Award Header
ARE YOU ELIGIBLE TO RECEIVE A 2012 PATHOLOGY VISIONS TRAVEL AWARD?

The Digital Pathology Association (DPA) will offer five conference travel
awards for pathology residents and residents doing fellowships to
attend the annual meeting of the DPA, Pathology Visions in Baltimore,
Maryland, October 28 – 31, 2012.

The awards of up to $2,000 each will help defray the cost of registration
and travelexpenses to this premiere event. Travel award applications are
due to the DPA by August 1, 2012. 

Learn more

HAVE YOU SUBMITTED YOUR POSTER ABSTRACT?

Presented posters at Pathology Visions will be judged by appointed
experts in the following categories:

    - "Best Poster By a Resident"
    - "Best Poster Submitted in the Research Category"
    - "Best Poster Submitted in the Education Category"
    - "Best Poster Submitted in the Clinical Category"

    - "Peoples' Choice Best Poster"

Awards will be handed out to the winner of each category at
Pathology Visions and a cash prize will be given to the winner
of the Resident category. The deadline for poster abstract
submissions is August 31, 2012.

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Minnesota is in the middle – Part 2

Turtle jockeyThe post below I wrote about three years ago and at that time did not mention that the caller was inquiring about my interest and ability to participate in the FDA panel looking at digital pathology back in the Fall of 2009.  That panel of course was put together which I have mentioned on prior occasion (see The FDA States, WSI Systems Are Not Class I Exempt (10/23/2009)).  

Nothing of significance happened until the FDA was invited to speak at Pathology Visions 2011 which I made a few notes about on a related story earlier this year (see Regulators regulating digital scanners).

 

Since that discussion there appears to be a standoff between manufacturers and the FDA.  

There does not appear to be any movement by either side short of the FDA opening up some positions for digital pathology specialists (more on this next week).

Manufacturers appear to be either (1) looking for opportunities overseas to sell products and services, (2) looking at leveraging cloud computing to facilitate consultations (from overseas or within the USA) or (3) waiting for each other to submit for the first intended use studies while the FDA waits for submissions after stating publicly that whole slide imaging devices would not be considered Class I devices (exempt) and cannot be treated as a laboratory developed test (LDT).  In the meantime, "Approved for Primary H&E Diagnosis" is not available in the US of A.

Based on the post below given my first interaction with FDA on this matter I cannot say that any of this is terribly surprising.  Neither side, particularly the FDA seems that intersted in putting the necessary resources behind this matter on behalf of the imaging or the laboratory community to facilitate necessary validation and clearances.  I can't blame the manufacturers here either.  It is going to take significant time and resources in a difficult business climate with slow adoption and use for what will have to be clearly defined intended uses and therefore limited use whether by tissue type, specimen source and/or defined or excluded histochemical/immunohistochemical/fluorescence stains.

When will the standoff end?

-----------------------------------------------------------------------------------------------------

Where's Mayo Clinic? Oh, Minnesota is in the middle (8/28/2009)

A couple of weeks ago - 6:30 AM phone call

This interaction actually happened and reminded me of this New Yorker cartoon about New York and “everything else”.

Caller: Dr. Kaplan, this is Mr. So and So from the [name of a government agency].  I am calling to inquire about your interest in reviewing grant submissions.  I hope you are not driving.

Me: No.  I was sleeping.

Caller: Good.  I hope I am not disturbing you but I need to know if you can come to [a city in the US] in January when we convene the review panel.

Me: What dates In January?

Caller: We do not know yet but I need to know right now if you can come.

Me: I suppose it depends a little bit on what I will be reviewing, if I have anything to offer and if I don't have a prior conflict.

Caller:  OK.  I will just need to collect some basic information such as your social security number, home address and place of employment. 

Me: Mayo Clinic.

Caller: Where is Mayo Clinic?

Me: Rochester, Minnesota.

Caller: Where is Minnesota?

At this point I start asking some questions about who this individual is, his civilian pay grade, where his office is located, how he knew where to contact me and check the caller ID for area code.

Me: Have you seen 'Taking Chance'?

Caller: No.

Me: 'Fargo'?

Caller: No.

Me: 'Grumpy Old Men'? 

Caller: No. What time zone are you in?

Me: Central.

Caller: Oh, Minnesota is in the middle.

Newyorkeverythingelse

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Huron Technologies Launches TISSUEscopeâ„¢ 4000XT for High Throughput Scanning

Waterloo, ON- Huron Technologies announces the launch of the TISSUEscope™ 4000XT with Autoloader Module for high volume and high throughput scanning. The fully-integrated system offers imaging of small and large glass slides for both brightfield and confocal fluorescent imaging modes and is designed to be compatible with all versions of TISSUEscope™ scanners.

Home0

The TISSUEscope™ 4000XT is capable of scanning up to 300-1x3” (25x75mm) glass slides as well as other non-traditional slide sizes including: 150-2x3” (50x75mm), 100-3x4” (75x100mm) and 25-large glass slides sizes for 4x5” (100x125mm), 5x7” (125x175mm) and 6x8” (150x200mm).

With its automatic scanning capability, the TISSUEscope™ 4000XT facilitates extended and overnight operations for labs which provide highly-efficient processes allowing staff to complete other tasks simultaneously.  By significantly increasing the number of slides scanned at one time, labs can enjoy substantial time-savings by reducing set-up delays but also extensive cost-savings through a decrease in lab expenses and processing time. 

The TISSUEscope™ 4000XT is easily controlled by the TISSUEscope™ client software where both automatic or manual control modes are available to customers.

With this launch Huron Technologies becomes the first in the industry to offer high-throughput scanning of small and large specimen samples for both brightfield and confocal fluorescence imaging.

 

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Why a cardiologist started a telemedicine business at Walmart

A cardiologist with an MBA has launched a telemedicine business starting with international retailerWalmart (NYSE: WMT) with the goal of providing affordable healthcare in areas underserved by providers.

Dr.Raj Shah, who runs a 37 year-old, 10-physician cardiology and internal medicine practice in Langhorne, Pennsylvania, is the founder of Telemed Ventures and CEO of Smart Care Doc. Having formed the company nearly three years ago, he opened its first telemedicine unit in Bensalem in suburban Philadelphia and another is scheduled to open in Willow Grove, Pennsylvania later this month.

Although suburban Philadelphia does not exactly fit the profile of an underserved area, Shah said he wanted to start with facilities nearby his office so he could more easily iron out any kinks with the business that might arise.

The unit includes a flat screen TV and a dentist-style chair and has a set of bluetooth-enabled medical devices administered by an on site nurse including a digital stethoscope, a handheld EKG device, a finger pulse reader and a digital thermometer. A light pen camera is used to look into ears, at the throat or skin lesions. All of the readings from these devices can be transmitted to the attending physician or entered into a computer and sent to the physician in real time. Nurses also provide immunizations, minor wound care, and other services.

Patients also get a personal health record referred to by the practice as a “patient passport.” It includes continuity of care records and documents, medical problems diagnosed from their encounters with Smart Care Doc physicians, prescribed medications, allergies and appointments. In the years before he started his telemedicine business, Shah had launched a patient passport business to help patients keep track of their records

Despite Shah’s presence at Walmart, his relationship with the big box retailer is only as a tenant, so he is not tied to a partnership agreement. But he hopes to expand the practice if enough people use the service to rural areas across the country where Walmarts are located. Walmart declined to comment.

“Every Walmart store has thousands of people coming to it every day,” said Shah. “My measure of success would be if 12-15 patients used the service each day.”

The company charges patients about $59 for checkups, low enough for people who don’t have insurance. In addition to primary care it plans to offer specialists in cardiology, gastrointestinal disorders, nephrology, dermatology and psychiatry.

So far the biggest use of telemedicine has been by the military and Veterans Affairs. Although the number of people who actually use telemedicine or would use it, were it offered to them remains to be seen, some telemedicine companies have added or have focused on specialties over concerns that there are not currently enough people using it for primary care.

Shah is currently looking for general practice physicians and specialists who would be interested in working for a telemedicine company, who can apply online.

To those who might point out it’s not the same as being in a physician’s office, Shah says with his business, physicians still have eye contact with their patients and have access to the same information that an in-person visit would generate.

The chairman of the company, Tom Pappas, is the former CEO of UnitedHealthcare of Pennsylvania.The company’s other board members include a colleague from his HeartCare Associates cardiology practice, faculty from Rutgers Business School and faculty and staff from Wharton Business School at University of Pennsylvania.

Although Pennsylvania Gov. Tom Corbett recently signed legislation to expand telemedicine’s use for Medicaid patients, along with 36 other states that provide reimbursement for Medicaid patients, there are obstacles to its expansion. U.S. Sen Tom Udall (D-NM) is drafting legislation that would streamline licensing that was expected to be introduced in the Spring.

Ultimately, Shah sees scope for the service being extended to other parts of the world like South America and Africa.

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Flagship Biosciences acquires IHCtech, a leading provider of research immunohistochemistry and histology services

Westminster, CO -- Flagship Biosciences announces today the acquisition of IHCtech LLC at the Colorado Anschutz Medical Campus. Founded in 2002, IHCtech has developed a strong reputation for high-quality advanced immunohistochemistry procedures, meeting the IHC and histology needs of pharmaceutical and academic investigators.

“We have partnered with Flagship Biosciences on a number of new techniques and approaches for quantitation in immunohistochemistry,” said Patsy Ruegg, owner and founder of IHCtech. “Their approaches to whole slide analysis and commitment to quantitative pathology makes a perfect partner with IHCtech’s expertise in high quality histology and immunohistochemistry. We enthusiastically look to further innovation by evaluating all aspects of the tissue chain -- tissue procurement, fixation and processing, with the ability to measure with whole slide analysis how each of these steps contribute to variability in the overall process.”

“While Flagship Biosciences has established strong partnerships with a number of highly respected IHC laboratories, both within the United States and internationally, this acquisition gives us the opportunity to internally evaluate tissue staining and implement new processes that better equip immunohistochemistry operations for use in quantitative pathology with whole slide imaging analysis,” said Dr. David Young, President of Flagship Biosciences. “Patsy Ruegg’s leadership in the area of high-quality research immunohistochemistry has been clear for many years. She has been a consistent expert in new IHC techniques like dual staining as well as a longtime leader in training of histology personnel.”

Flagship Biosciences specializes in tissue-based companion diagnostics, IHC biomarker development and histopathology assessment of discovery, safety and toxicity using brightfield and fluorescent whole slide imaging. The company provides a full service of tissue analysis for drug and device development, including tissue procurement, tissue preparation and immunohistochemistry, whole slide quantitative computer-based evaluation, with all services overseen by veterinary and medical anatomic pathologists

IHCtech provides high-quality histology, immunohistochemistry, and immunofluorescence to academic and pharmaceutical clients. With over 350 optimized research IHC antibodies, IHCtech brings a wealth of knowledge and expertise to the tissue analysis process.

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Cloud Software for Microscopy and Image Analysis

Power of  cloud computing and convenience of web applications for biomedical and industrial imaging. 

Upload digital slides from any microscope
Collaborate in real time with Live Markers
Access your work anywhere
Share with a single click
See more information with image overlays
Get results with automated analysis applications

Virtual Microscopy

Simagis Live is designed to support easy upload, publishing, sharing and real-time review of digital microscopy slides on the web. Support for multiple image layers enables multi-dimensional imaging. You can review, annotate, tag and measure images with multiple collaborators on-line at the same time. Sign up for free Virtual Microscopy service, upload your images start sharing your digital slides with authorized users anywhere in the World in minutes.

Cloud-based Image Analysis

Harness the power of the cloud computing to analyze images of any size for any number of users without need to install any desktop software or hardware. All you need is a web browser. Using Simagis Live server you can run complex automated image analysis on composite multi-layered images, create data overlays, and download results from measurement database, all from friendly web interface. Use dozens of available applications or request custom solution for your specific analysis from our Custom App team.

Mobile Microscopy Applications

Simagis Live platform enables emerging field of mobile microscopy.  With portable microscope connected to the web via cell phone of other wireless device, the imaging data can be synchronized with cloud-based Simagis Live applications which will analyze and deliver images for review to experts anywhere in the world (see example of mobilecellscope).

Global Enterprise Solutions

Simagis Live enables virtualization of microscopy processes across the organization. Our technology makes it easy to integrate your automated imaging equipment and build seamless virtual workflow with users anywhere in the world. Integrate your collaborative research, lab service or quality control process with single image analysis server that can receive, store, analyze and share images across your organization. Choose in-house installation or scale processing power using cloud-computing platform to meet your needs.

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

NinePoint Medical Receives European CE Mark Approval and ISO Certification for NvisionVLE Imaging System

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

NinePoint Medical, Inc., an emerging leader in the development of medical devices for in vivo pathology, today announced that it has received European CE mark approval for the NvisionVLEImaging System. The CE Mark is for the companys optical endomicroscopy imaging devices for diagnosis of mucosa and submucosa diseases. The company has also received ISO 13485:2003 certification, an international standard governing the requirements of a quality management system for medical devices and related services, for the companys Cambridge facility. The CE marking or Conformite Europeene certifies that a product has met European Union (EU) requirements for marketing in Europe.

The ISO certification and CE mark approval are important milestones for NinePoint Medical and, along with our recently announced 510(k) clearance from the FDA, strongly position the NvisionVLE Imaging System for a commercial launch in 2013, said Charles Carignan, M.D., president and chief executive officer of NinePoint Medical.

NinePoint Medical recently initiated a clinical trial to evaluate high-resolution optical imaging of Barretts esophagus using the NvisionVLE Imaging System. Barretts esophagus is one of the most common precursors to esophageal adenocarcinoma, the fastest growing cancer in the Western world. With the CE Mark, the company will now add two sites in Europe to the clinical trial. In addition, in January 2012 the company announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its NvisionVLE Imaging System for use as an imaging tool in the evaluation of human tissue microstructure by providing two-dimensional, cross sectional, real-time depth visualization. The NvisionVLE Imaging System is the first volumetric, optical coherence tomography (OCT) device cleared by the FDA for endoscopic imaging that generates cross sectional and longitudinal images simultaneously, in real time.

About NinePoint Medical, Inc.

NinePoint Medical, Inc. is a transformational medical device company developing innovative, real-time, in vivo pathology devices focused on dramatically improving patient care. Through its proprietary NvisionVLE Imaging System, NinePoint intends to bridge the gap between the diagnosis and treatment of disease. The NvisionVLE Imaging System will enable physicians and pathologists, for the first time, to view real-time, high-resolution, volumetric images of organs and tissues up to 3mm deep at better than 10 micron resolution. Initially, NinePoint is focusing on devices that enable real-time, endoscopic screening and surveillance of diseases of the mucosa of various tissues that are often precancerous. Eventually, the company intends to develop medical devices that provide physicians with immediately actionable information, which will allow them to diagnose and treat patients during the same procedure. This convergence of access, diagnosis and treatment during one procedure is expected to improve patient experiences and outcomes, improve the efficiency of care and provide important savings to the health care system. Headquartered in Cambridge, Mass., NinePoint is backed by Third Rock Ventures and Prospect Venture Partners. For more information, please visit http://www.ninepointmedical.com.

Visit link:
NinePoint Medical Receives European CE Mark Approval and ISO Certification for NvisionVLE Imaging System

Halfpenny Technologies Appoints Brian Muck as EVP of Sales and Marketing

BLUE BELL, Pa.--(BUSINESS WIRE)--

Halfpenny Technologies, Inc.a leading provider of clinical data integration solutions specializing in laboratory, pathology and physician electronic medical record (EMR) system interoperabilitytoday announced it has named Brian Muck executive vice president of sales and marketing.

Brians extensive experience in healthcare, sales and business development will enable us to deepen our customer relationships and strong business foundation, says Tim Kowalski, president and chief executive officer of Halfpenny Technologies. His ability to develop and execute sales strategies will be integral to our growth in the hospital and commercial laboratory markets, as well as into new segments.

With 22 years of business development experiencenine of which are in sales programs and managementMuck brings robust expertise around driving revenue and profit growth in strategic and complex environments to Halfpenny.

We are pleased to be able to draw upon Brians vision and skills to help us achieve our growth goals for our health information exchange (HIE) solutions with existing and prospective customers, says Charles Halfpenny, the companys founder and chief technology officer. Brian has an impressive track record in healthcare, and he understands the complex nature of the challenges facing our industry today.

Before joining Halfpenny, Muck served as vice president of sales in emerging markets for Vitera Healthcare Solutions. Prior to Vitera, Brian held positions in sales and sales management at BrainLab, Varian Medical Systems, Edwards Lifesciences, GE Healthcare and Hewlett-Packard. He has also worked closely with the Office of the National Coordinator (ONC), Beacon Communities, Quality Improvement Organizations (QIOs), and state and regional HIEs. In addition, Muck co-chaired a workgroup within the ONC/HIMSS EHRA collaborationthe EHR Adoption Community of Practice.

About Halfpenny Technologies, Inc.

Halfpenny Technologies is a leading provider of healthcare connectivity and integration solutions for Health Information Exchange. The company utilizes its depth of knowledge and real world clinical experience to meet the increasing demand for connectivity to physician electronic medical record (EMR) systems. Through its proprietary Integration Technology Framework (ITF), Halfpenny Technologies delivers clinical data integration and connectivity solutions that enable hospitals and laboratories to receive, process and respond to physician-initiated requests for ancillary services. Halfpennys targeted solutions cover the full spectrum of health information exchange to provide reliable, secure and efficient exchange of clinical information while also facilitating the flow of patient, financial and administrative data between physician practices, laboratories, hospitals and health plans. The company has established a national reputation for delivering innovative integration and connectivity technology solutions for its clients. For more information, visit http://www.halfpenny.com.

Go here to read the rest:
Halfpenny Technologies Appoints Brian Muck as EVP of Sales and Marketing

Global Anxiety Disorders Industry

NEW YORK, June 5, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Anxiety Disorders Industry

http://www.reportlinker.com/p0552771/Global-Anxiety-Disorders-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

This report analyzes the worldwide markets for Anxiety Disorders in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 63 companies including many key and niche players such as AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Forest Laboratories, Inc., GlaxoSmithKline Plc, H. Lundbeck A/S, Mylan, Inc., Neurocrine Biosciences, Inc., Pfizer, Inc., Ratiopharm, Sanofi, UCB SA, Valeant Pharmaceuticals International, and Watson Laboratories, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

To order this report:

Read more:
Global Anxiety Disorders Industry

Second opinion avoids unneeded major surgery

Ginny Hillis says when mixedup pathology reports indicated breast cancer, she avoided unnecessary surgery by Dr. Barbara Heartwell by fighting for a second opinion.

"You have to be your own advocate, you can't be passive when you get a catastrophic diagnosis," the 66-year-old retired lawyer stressed as she recounted her experience in 1995, years before the high-profile cases in which Heartwell performed surgery on local women - two breast removals and a lumpectomy - for breast cancer they didn't have.

Hillis said the most recent case that came to light last month, of a woman receiving an unnecessary lumpectomy because of a mistake by a pathologist at Windsor Regional Hospital, reconfirms her belief: "I know it isn't easy but get a second opinion."

Hillis said that in her case there were two pathology reports, a preliminary study of the tissue sample taken from her breast that indicated cancer and a more detailed report that said she was cancer-free.

But the sequence of those reports was switched, so it appeared the more detailed report concluded she had breast cancer, she said. Heartwell was recommending an axillary lymph node dissection to find out if the cancer had spread beyond the breast, Hillis said.

She claims that Heartwell discouraged a second opinion.

Hillis said Heartwell is "a very talented surgeon.

"It was a pathology error. But my problem with (Heartwell) was the outright flat denial that I needed a second opinion."

Through Hotel-Dieu Grace Hospital spokesman Steve Erwin, Heartwell's lawyer Andrea Plumb stated that Heartwell denies blocking Hillis's access to a second opinion.

Plumb said Heartwell advised Hillis to contact the hospital's pathology department directly with her request and that the department stood by its results.

Here is the original post:
Second opinion avoids unneeded major surgery

Check Out CGL’s Exome Sequencing Test

6a00e009846ac188330168eb80fe20970c-320wiAt the ASCO Annual Meeting in Chicago (June 1 to June 5), the Cancer Genetics Laboratory and the Whole Genome Laboratory at Baylor College of Medicine (BCM) will officially announce the clinical implementation of the Cancer Exome Sequencing test. This test is the result of a collaboration between genomic scientists, clinical laboratory scientists, geneticists and oncologists at BCM to provide reliable cancer genome-wide analyses that are carefully annotated and interpreted for clinical significance.

The Cancer Exome Sequencing test follows on the successful 2011 launch of germline exome sequencing for the evaluation of inherited disorders. The Cancer Exome Sequencing test focuses on somatically acquired genetic alterations in tumors and applies the power of next-generation sequencing technology to cancer genetics in a CAP/CLIA-approved setting with clinical interpretation of sequence information. This test is ordered by a physician and may be used when a patient’s oncology management would benefit from identifying genetic changes in the tumor that predict sensitivity or resistance to a variety of therapeutic regimens.

Cancer Exome Sequencing is poised to change the current paradigm of genetic testing for cancer patients by focusing on whole exome analysis of a patient’s tumor. The term exome refers to the portion of the human genome that contains the DNA sequence that directs protein synthesis. These functionally important regions of DNA are referred to as exons. The 22,000 known genes are comprised of approximately 180,000 exons and represent about 3% of the genome. Most errors in DNA sequence that lead to altered protein function in tumors are located in the exons, therefore, exome sequencing is an efficient method for tumor DNA sequence analysis to uncover genetic causes for tumor behavior.

The principle of the test is to sequence nucleotide by nucleotide, the human exome of normal tissue (generally blood) and a sample of tumor tissue to a depth of coverage necessary to determine sequence variations that are unique to the tumor (somatic mutations) with high sensitivity. Point mutations, insertions and deletions of the exome are potentially discoverable and could be considered important for cancer management depending on the defect and available evidence. These sequence variations are then categorized based on their role in defining a specific tumor property or tumor sensitivity to established and novel therapeutic approaches. This test will report all somatic mutations identified in the tumor genome and classifies them according to clinical utility based on careful evaluation of functional and clinical evidence in the medical/scientific literature and the availability of agents targeted to a specific gene or pathway. This test also reports the presence of inherited (germline) genetic variations in selected genes known to increase the risk for cancer (e.g. APC, TP53, and others).

Please join Baylor College of Medicine at the ASCO Annual Meeting (Booth #22082) for additional information on the Cancer Exome Sequencing test and to meet with BCM Medical Directors to further discuss this test and other services.

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Smart Imaging Technologies adds archiving and storage of digital slides in Aperio SVS format

Logo_sitWith the latest version of Simagis Live server, administrators have an option to archive and store digital slides in a version of TIFF format also known as BigTiff or Aperio SVS file format. 

Advantage of this slide format, introduced to Digital Pathology by Aperio, is that it is open and supported by the latest version of public Libtiff library. It is also supported by free desktop software applications such as Aperio’s ImageScope slide viewer.

Simagis Live servers support various compression options for SVS files including both lossy JPEG compression and lossless options such as JPEG2000 or LZW that may be required by FDA in the future to preserve diagnostic image quality.

With Simagis Live servers, users already could upload, view, share and analyze digital slides from different scanners including Aperio, Hamamatsu, Mirax, Leica, Mikroscan, DigiPath, Huron and others. Now, with the option to store slides in SVS format, they get single unified digital slide archive interchangeable with other servers and desktop viewers. This feature is especially valuable for organizations that have several scanners from different vendors and need an integrated solution for viewing, sharing and analyzing digital slides.

This option is also valuable for scanner manufacturers who use Smart Imaging Technologies servers under their own brands to provide slide sharing and analysis solutions to end-users. They can assure users that slides are stored in an open format accessible by third-party software.

About Smart Imaging Technologies

Logo_im_solutionWe provide web servers and applications for viewing, sharing and analyzing whole slide images. Our servers support most digital slide formats, can be easily integrated with various scanners for a single click slide upload, and deployed on premises or on High Performance Computing Cloud.  For details about technology and solutions manufacturers and integrators may contact support@simagis.us .

End-users can learn more and sign-up for free web service at web-pathology.net.

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

X-rays, digital pathology and iPads: The network healthcare evolution

PathCentralScreenShot-1_5-11-2012

 It is just a matter of time that pathologists too will recognize the value of wireless connectivity, coordinating care, analytical tools for diagnosis and management and closer follow up, all enabled through mobile computing and digital pathology.

Xray-ipadsAt the rate technology has changed everything else in our lives, by now we should have the equivalent of tricorders in our smartphones—instant access to our health statistics collected by sensors in our clothes and pulled into our individual health history in the cloud. We should be able to Skype our physician, text our pharmacist, and get both a blood sugar measurement and an MRI at Starbucks while waiting for a grande latte.

Except for the MRI part, all of that is doable today. Thanks to the big stick provided by the Affordable Care Act in the US, some healthcare organizations are pushing more aggressive use of network bandwidth and cloud technology:

  • Monitoring patients’ health more proactively with networked devices, ranging from wirelessly networked medicine bottle lids to worn or embedded sensors that report back on vital signs;
  • Coordinating care with the help of analytic tools in the cloud and a wealth of individual and collective patient data; and
  • Connecting physicians directly with patients over PCs or mobile devices for between-appointment follow-ups.

Those things can’t be pulled off without cloud technology, whether it’s hosted internally in a health organization’s data center or elsewhere. But ask any random sampling of physicians, technologists, and health industry observers. They’ll tell you technology isn't restraining the next big paradigm shift in health care. The bandwidth is willing.

“It’s less about the technology holding the industry back, and more about the reimbursement model for healthcare,” says Kenneth Kleinberg, senior director of research and insights at The Advisory Board Company, a global healthcare research, technology, and consulting firm. “Quality hasn't been rewarded, physicians don’t have incentives to share data, and patients are freaked out about privacy. Healthcare isn't a system—it’s a bunch of individual entities looking out for themselves. Just adding more bandwidth to a broken system doesn't work.”

Real technological change in health care requires changing the “work culture” of health organizations and people’s confidence in health IT systems, says Harry Kim, senior director of Hewlett-Packard’s healthcare group. But other complex (and heavily regulated) businesses have embraced change long ago. Citing ATMs, Kim says, “If we can trust our money to a machine, we can do it with healthcare.”

That’s why health organizations are looking outside of their industry for inspiration. “The companies bringing the biggest changes to medicine today are companies like Cisco, EMC, Apple, and Microsoft,” says Dr. Elliot Fishman, Director of Diagnostic Imaging and Body CT at Johns Hopkins Medical Center. Technology from the consumer sector (such as mobile devices and apps, cloud computing, and even gaming) is seeping into the healthcare field and being seized upon by care providers to improve the connection between physician, patient, and data.

To get an idea of how bandwidth can change medicine, we talked to people on the front lines of medical technology at two of the most well-known hospital systems in the US: Johns Hopkins and the University of Maryland Medical Center. We also caught up with technology and digital health service providers. What we got was a snapshot of organizations that are already working to transform medical care with networked technology, while trying to overcome organizational inertia to make it happen.

Driven by data

The first wave of change that healthcare organizations have dealt with (or are still dealing with) is what Kim calls the “digitization of sick care.” Nearly 80 percent of healthcare is dealing with chronic illness. To improve care for patients with chronic health problems, health providers need to be able to effectively monitor and capture the right data from them, pull it back into electronic medical records, and make it available to both patients and physicians to act upon.

The problem is that many health record systems weren't built to handle those tasks. Healthcare systems have had electronic health records for decades; the problem is the systems lack standardization. These carry with them the sorts of software and schema hangovers that plague every data integration project.

“At Hopkins, it started a long time ago with a longitudinal patient record that pulled in from all our systems,” says Stephanie L. Reel, Vice Provost of Johns Hopkins University, Vice President of Information Services at Johns Hopkins Medicine, and CIO for both the university and hospital. The system acts as a repository for information from all of the hospital systems’ various health systems.

“But in spite of the fact that I think we've done a good job over the last 25 years, we've now realized we didn't,” Reel says. The effort required to get all of the data normalized from each of the systems was “too expensive, cumbersome, and not always possible.”

So Hopkins is replacing its homegrown system with one from Epic, a hosted system with a single, patient-centric database. Reel says that when it’s implemented, the system will “give each patient control over his or her own records.” Patients finally gain complete access. Since it’s a single integrated system, all of an individual's data is there for each caregiver—their allergies, test results, medications, etc. Epic's portal can even be accessed through mobile apps for Apple iOS and Android devices.

Epic's Canto electronic medical record app for iPad.

But on top of that, the data will also be used to mine information on how well different courses of care worked for patients. This should help tailor care based on patients' own conditions and the outcomes of people with similar cases. “You can look at a population base that has benefited from treatment,” Reel said. “We can learn from our own cases, but also if done appropriately, can learn from interventions elsewhere. This gives us the opportunity to do personalized medicine—based on previous cases, we can be able to predict when patient will benefit from one type of intervention or another—or, from their genetic makeup, might be able to decide if treatment won’t help.”

BYOD medicine

Physicians aren’t waiting for their central IT departments to achieve the nirvana of centralized healthcare data. They’re finding their own ways to get access to the information they need, when they need it—pushing health providers to build Web portals and other applications that give them access to medical records anywhere. One of the most visible signs of change is the adoption of the iPad and other mobile devices by physicians.

Thanks to more reliable and more widely available wireless bandwidth, the iPad has become an essential tool for clinicians. Last October, the Department of Veterans Affairs moved to open up its network so that doctors could use their own mobile devices. While other health systems have been slow to officially adopt the iPad and other devices, John Kornak, Director of Telehealth at the University of Maryland Medical Center says, “A BYOD (bring your own device) mentality is starting to take shape among physicians, and more mobile apps are starting to find their way into use.”

Kornak says that there is a strong push from doctors to find mobile apps that make it easier and more seamless for them to connect to health data such as charts and radiology images. “Physicians are telling us if we don’t have [the apps they need], we need to have a development partner and build it ourselves. They're really urging us to not focus on what the standards are—we need to be open to any devices on market, and keep them in mind when building solutions.”

One of the most obvious applications for the high-resolution screen of the latest iPad is displaying medical imagery. By pulling up images from CT scans and MRI scans on their iPads, Hopkins’ Dr. Fishman says surgeons now use the iPad to explain procedures to patients more effectively. “Doctors can look at their cases in real time. Now my clinicians are looking at the information I generate as it’s created. They can pull down CT slices in 2 seconds. It’s very fast and interactive. They can bring the image to the bedside or in the office.”

That mobility and ease of access pays off in another way: time. “When you speak to surgeons at Hopkins,” says Fishman, “they say that they save about an hour of time each day from using the iPad. And that’s a big deal—instead of going home when their kids are asleep, they get home when their kids are awake.” Fishman says he’s been at the beach and on airplanes and has been able to look at radiology images for consults.

That power doesn’t just come from the digitization of raw information, though. It only works, Fishman says, when the networking piece becomes transparent. “The end-user experience has to be that it just happens," he says, "not typing 20 codes in for access and hoping that it works.”

Read more.

Sean Gallagher / Sean is Ars Technica's IT Editor. A former Navy officer, systems administrator, and network systems integrator with 20 years of IT journalism experience, he lives and works in Baltimore, Maryland.

 

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog